Analysts Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $15.80

Zura Bio Limited (NASDAQ:ZURA) has been given an average rating of “Buy” by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.80.

ZURA has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research note on Tuesday. Chardan Capital cut their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 8th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th.

Insider Activity

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 22.10% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

Hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC purchased a new stake in Zura Bio in the 2nd quarter valued at $43,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Zura Bio during the 3rd quarter valued at about $46,000. Renaissance Technologies LLC grew its holdings in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Zura Bio in the third quarter valued at about $62,000. Finally, Valence8 US LP acquired a new stake in Zura Bio during the third quarter worth about $71,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Stock Performance

NASDAQ ZURA opened at $2.50 on Wednesday. Zura Bio has a 1 year low of $2.00 and a 1 year high of $6.35. The company has a fifty day moving average of $3.38 and a 200 day moving average of $3.64.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, analysts predict that Zura Bio will post -0.65 EPS for the current year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.